Response to a post that said K was stalled, OM data was weak, and P was a failure thus IPIX was a total failure:
Fear the boogeyman, not the facts.
Stalling of K?
The company has no money to further the Kevetrin pipeline at the current time. Even a knucklehead should be able to understand this. As to the science, show one area in which Kevetrin to date has shown weakness. Currently held up because it clears the body too quickly to allow it to be delivered via IV. Problem? NO, as this feature means that it will not cause systemic buildup, currently a major problem with other cancer treatments that are highly toxic and cause dangerous side effects. Get the pill formulated, tested, and accepted by the FDA and Kevetrin continues on its way to possibly turning cancer treatment on its head. So all in all, Kevetrin is currently halted but soon, when funds become available, it continues to rock and roll.
Poor OM results?
Where does this BS come from? IPIX was so happy with it that they posted a blog comparing it to the only real competitive alternative going thru trials and it showed much more effective and easier to deliver. So since the science cannot be questioned, we move to say that it must have had poor results because a deal has not come forward yet? Not that mgt is holding out to get a fair value for it and thus have rejected any and all offers to date? The recent PRs over the last couple of months don't indicate that a near term deal to get it licensed may be on the table or even that mgt has decided that they may make a deal for IBD so that they can take OM thru P3 by themselves to really jack the value? Who knows what is really going on? Certainly not we posters on this board yet others post that it can only mean a very negative future for it. Disgraceful attempt to muddy the waters with absolutely no facts to back it up.
Failed P? Maybe so, most likely so in fact, but go to any doctor and ask them the odds that 3 products in a company pipeline would all make it thru trials to commerciality at the same time? They would say more likely one would win a lottery. It had a good chance to succeed, appears to have hit a stone wall, but whether it failed or succeeded has absolutely no bearing whatsoever on B or K succeeding.
If one indication of IPIX succeeds, shareholders make out like bandits. If one platform succeeds, shareholders make out like kings. If more than one succeeds, shareholders are lottery winners.
Fear the boogeyman, not the facts.
Stalling of K?
The company has no money to further the Kevetrin pipeline at the current time. Even a knucklehead should be able to understand this. As to the science, show one area in which Kevetrin to date has shown weakness. Currently held up because it clears the body too quickly to allow it to be delivered via IV. Problem? NO, as this feature means that it will not cause systemic buildup, currently a major problem with other cancer treatments that are highly toxic and cause dangerous side effects. Get the pill formulated, tested, and accepted by the FDA and Kevetrin continues on its way to possibly turning cancer treatment on its head. So all in all, Kevetrin is currently halted but soon, when funds become available, it continues to rock and roll.
Poor OM results?
Where does this BS come from? IPIX was so happy with it that they posted a blog comparing it to the only real competitive alternative going thru trials and it showed much more effective and easier to deliver. So since the science cannot be questioned, we move to say that it must have had poor results because a deal has not come forward yet? Not that mgt is holding out to get a fair value for it and thus have rejected any and all offers to date? The recent PRs over the last couple of months don't indicate that a near term deal to get it licensed may be on the table or even that mgt has decided that they may make a deal for IBD so that they can take OM thru P3 by themselves to really jack the value? Who knows what is really going on? Certainly not we posters on this board yet others post that it can only mean a very negative future for it. Disgraceful attempt to muddy the waters with absolutely no facts to back it up.
Failed P? Maybe so, most likely so in fact, but go to any doctor and ask them the odds that 3 products in a company pipeline would all make it thru trials to commerciality at the same time? They would say more likely one would win a lottery. It had a good chance to succeed, appears to have hit a stone wall, but whether it failed or succeeded has absolutely no bearing whatsoever on B or K succeeding.
If one indication of IPIX succeeds, shareholders make out like bandits. If one platform succeeds, shareholders make out like kings. If more than one succeeds, shareholders are lottery winners.
10
